+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

How recombinant insulin analogs improve insulin therapy of diabetes mellitus: pathophysiology, clinical practice and recommendations



How recombinant insulin analogs improve insulin therapy of diabetes mellitus: pathophysiology, clinical practice and recommendations



Medical Science Monitor 7(4): 848-859



According to the latest prognoses, 300 million people are expected to suffer from diabetes (particularly type 2) in 2025; diabetes will become a new epidemics of the coming century. Therefore it is so important to get acquainted with the pathomechanism of diabetes-related disorders and the possibilities of effective treatment. During the last decade, numerous prospective epidemiological studies have been completed, which have considerably extended our knowledge of the pathomechanism of disturbances and their effect on late complications of diabetes. Resistance to insulin has an important role in the etiology of type 2 diabetes. However, there is substantial evidence indicating that impairment or regression of rapid insulin secretion phase at the early stage of the disease is a factor of no lesser importance. The lack of appropriate insulin concentration after the stimulation by food ingestion (first 30 min after the meal), leads to permanent, treatment-resistant hyperglycemia. The postulated attempts to obtain a 'nearly normoglycemic' condition, as well as the results of prospective epidemiological studies proving that achieving this aim improves the prognosis of diabetic patients, prompt the researchers to search for the drugs or treatment schedules, which could effectively restore the impaired insulin secretion, and its early phase in particular, in type 2 diabetes. Human insulin analogs and their pre-formulated commercially available mixtures seem very promising in this respect.

(PDF emailed within 1 workday: $29.90)

Accession: 046280926

Download citation: RISBibTeXText

PMID: 11433220


Related references

Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 350(9086): 1199-1204, 1998

Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia. Diabetes Therapy 2018, 2018

Pathophysiology of postprandial hyperglycemia in patients with insulin dependent diabetes mellitus on conventional insulin therapy. Clinical Research 35(1): 194A, 1987

Single daily injection of a mixture of three insulins (regular insulin, protamine-zinc insulin and NPH insulin) in the therapy of insulin-unstable and insulin-resistant diabetes mellitus. La Presse Medicale 61(70): 1428-1430, 1953

Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. Journal of Clinical Endocrinology and Metabolism 82(4): 1181-1187, 1997

The effects of co-therapy with recombinant human insulin-like growth factor I and insulin on serum leptin levels in adolescents with type 1 diabetes mellitus. Pediatric Diabetes 2(1): 25-29, 2004

Transferring patients with insulin-dependent diabetes mellitus from animal-source insulins to recombinant DNA human insulin: clinical experience. Clinical Therapeutics 11(3): 319-330, 1989

New systems for sub cutaneous insulin delivery insulin pump and multiple insulin injection therapy in insulin dependent diabetes mellitus. Tidsskrift for den Norske Laegeforening 104(13): 852-861, 896, 1984

Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Diabetes Care 7 Suppl 1: 100-105, 1984

Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. Journal of Clinical Research in Pediatric Endocrinology 1(4): 181-187, 2011

The therapeutic efficacy of human insulin (recombinant DNA) in patients with insulin-dependent diabetes mellitus: a comparative study with purified porcine insulin. Diabetes Care 5 Suppl 2: 73-77, 1982

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clinical Endocrinology 49(6): 739-746, 1999

Clinical consequences of intranasal insulin therapy in insulin-dependent diabetes mellitus. Ugeskrift for Laeger 158(24): 3451-3455, 1996

Clinical characteristics inheritance of diabetes mellitus and insulin secretion in the non insulin dependent diabetes mellitus subgroup called maturity onset diabetes in the young. Diabetes Research & Clinical Practice (SUPPL 1): S146, 1985

Insulin therapy in diabetes mellitus. Clinical experiences with a highly purified swine insulin. Die Medizinische Welt 32(20): 795-797, 1981